Results 81 to 90 of about 8,209 (210)

“Nomen Omen: The Myth of God Janus”

JEADV Clinical Practice, EarlyView.
Alba Guglielmo
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis

Journal of Dermatological Treatment
Background Janus kinase 1 inhibitor upadacitinib is therapeutically effective for atopic dermatitis (AD). However, predictive factors for high responders to upadacitinib have not been established in real-world clinical practice.Objectives To identify ...
Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda   +5 more
doaj   +1 more source

Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment [PDF]

Achieving the primary treat-to-target (T2T) goal in rheumatoid arthritis (RA) remains challenging for many patients, reflecting limitations in the effectiveness of existing treatments.
Corominas, Hèctor, Díaz Torne, César, Martinez-Molina, Cristina, Park, Hye S., Vidal, Silvia   +4 more
core   +1 more source

Erosion Regression in Patients with RA After Upadacitinib-A Pilot Study Using High Resolution Peripheral Quantitative Computed Tomography

Journal of Clinical Rheumatology and Immunology
Background: Janus kinases inhibitor (JAKi) is a potent drug in treating patients with rheumatoid arthritis (RA). However, the effect of JAKi on finite structural changes remained uncertain.
Isaac T Cheng, Ho So, Evelyn H Chow, Qihan Wu, Martin Li, Vivian W Hung, Ling Qin, Chun Kwok Wong, Lai Shan Tam   +8 more
doaj   +1 more source

Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)

Dermatology and Therapy
Introduction The Aiming High in Eczema/Atopic Dermatitis (AHEAD) guidelines recommend achieving minimal disease activity (MDA) in atopic dermatitis (AD), defined as simultaneous achievement of optimal treatment targets for at least one clinician- and one
Jonathan I. Silverberg, Melinda Gooderham, Norito Katoh, Valeria Aoki, Andrew E. Pink, Yousef Binamer, Brad Glick, Petra Staubach, Brian Calimlim, Chao Li, Ayman Grada, Alvaro Moreira, Wan-Ju Lee, Andreas Wollenberg   +13 more
doaj   +1 more source

Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis

International Journal of Dermatology, EarlyView.
ABSTRACT Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder characterized by hyperkeratotic nodules and a debilitating itch–scratch cycle. Conventional therapies have limited efficacy and safety issues, while biologics have recently emerged as a promising alternative.
Andrea Lancz, Fanni Adél Meznerics, Renáta Árok, Anna Sára Lengyel, Bence Szabó, Péter Hegyi, Norbert Kiss, András Bánvölgyi   +7 more
wiley   +1 more source

Treatment of atopic dermatitis with upadacitinib: adcare single center experience

Frontiers in Medicine
IntroductionThe role of upadacitinib in the management of moderate to severe atopic dermatitis seems promising, but more data on its efficacy and safety are needed.
Daria S. Fomina, Daria S. Fomina, Olga A. Mukhina, Valeria I. Mikhailova, Marina S. Lebedkina, Elizaveta L. Sedova, Elena N. Bobrikova, Olga G. Elisyutina, Olga G. Elisyutina, Elena S. Fedenko, Tair T. Nurpeisov, Tair T. Nurpeisov, Alexander V. Karaulov, Mar’yana A. Lysenko, Mar’yana A. Lysenko, Luis Felipe C. Ensina   +15 more
doaj   +1 more source

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

BMC Rheumatology, 2018
Background Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.
Julie M. Parmentier, Jeff Voss, Candace Graff, Annette Schwartz, Maria Argiriadi, Michael Friedman, Heidi S. Camp, Robert J. Padley, Jonathan S. George, Deborah Hyland, Matthew Rosebraugh, Neil Wishart, Lisa Olson, Andrew J. Long   +13 more
doaj   +1 more source

Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-year data from SELECT-COMPARE [PDF]

Introduction: This study aimed to describe the long-term efficacy and safety of upadacitinib and adalimumab through 228 weeks following immediate switch to the alternate therapy with a different mechanism of action (MoA) in patients with rheumatoid ...
Bassette, Louis, Blanco Alonso, Ricardo, Chan, Kelly, Fleischmann, Roy, Khan, Nasser, McDearmon-Blondell, Erin, Mysler, Eduardo, Penn, Sara K., Song, Yanna, Van den Bosch, Filip   +9 more
core